硼替佐米聯(lián)合沙利度胺地塞米松治療對(duì)多發(fā)性骨髓瘤患者炎癥指標(biāo)免疫功能的影響

打開(kāi)文本圖片集

Efficacy bortezomib，thalidomide and dexamethasone on patientswith multiple myeloma Zhu Ruifeng， Zhou Shuiyang， Bao Weiying， Wang Hengshi， Fan Lu， Wang Liping， Wang Xiaoyan. ， ， ，2O1699，

【Abstract】ObjectiveThe eficacy bortezomib，thalidomide，and dexamethasone in treating patients withmultiple myeloma was investigated.MethodsA total 10O multiple myeloma patientsadmited to District Central in between August 2O2O and August 2023 wereenrolld assubjects for this study.These patients were randomlyassigned into two groups （5O each） by a random number table.The control group received thalidomideand dexamethasone，whereas theobservation group was administered bortezomib inaddition tothecontrol group'sregimen.Theclinical eficacy，inflammationmarkers，immune function，bone metabolism indicators，and adverse reactions between the two groups were compared.ResultsThe observation group demonstrateda higheroverall clinical efective rate compared tothe control group，with astatistically significant difference （P<0.05） .Post-treatment levels vascular endothelial growth factor （VEGF）， interleukin-6 （IL6），C-reactive protein （CRP）， interleukin-17 （IL-17），T lymphocyte subset CD 8+ ，and type I collagen C-terminal peptide（CTX-I） were lower in the observation group than those in the control group.Conversely，CD 4+ ，CD 3+ ， CD4+/CD8+ratios，osteocalcin （BGP），and alkaline phosphatase （ALP）levelswere higher，with all diferences being statistically significant（ P <0.05）.Adverse reactions between the two groups were comparable，with no statistically significant difference（ P >0.05）.ConclusionThecombineduse bortezomib with thalidomideand dexamethasoneinthe treatment multiplemyeloma patientsyieldssignificant therapeutic benefits，enhances immune function，reduces inflammatoryresponses，improvesbone metabolism，andexhibitsa high level safety.

【Key Words】Multiple myeloma;Dexamethasone;Bortezomib； Thalidomide； Inflammatory markers; Immu-nity

多發(fā)性骨髓瘤是一種惡性血液疾病，骨髓漿細(xì)胞惡性增殖是該病形成的主要原因，以骨痛、出血、腎功能不全、貧血等為臨床表現(xiàn)，若控制不理想，會(huì)對(duì)機(jī)體內(nèi)其他組織、器官造成嚴(yán)重?fù)p傷，大大降低了患者生存質(zhì)量[12。（剩余5981字）